Details for Patent: 10,966,939
✉ Email this page to a colleague
Which drugs does patent 10,966,939 protect, and when does it expire?
Patent 10,966,939 protects EPIDIOLEX and is included in one NDA.
This patent has thirty-two patent family members in nineteen countries.
Drugs Protected by US Patent 10,966,939
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 10,966,939 | ⤷ Subscribe | Y | USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME | ⤷ Subscribe | |||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 10,966,939 | ⤷ Subscribe | Y | USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,966,939
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015332212 | ⤷ Subscribe | |||
| Australia | 2021204353 | ⤷ Subscribe | |||
| Australia | 2023258400 | ⤷ Subscribe | |||
| Brazil | 112017007777 | ⤷ Subscribe | |||
| Canada | 2963208 | ⤷ Subscribe | |||
| Canada | 3232241 | ⤷ Subscribe | |||
| Cyprus | 1123229 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
